Brief: Sequana Medical FY Net Loss Widens To EUR 23.6 Million

Sequana Medical NV

12/04/2022 06:16

April 12 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES 2021 FULL YEAR RESULTS AND 2022
OUTLOOK
    * TOTAL CASH POSITION OF €9.6 MILLION AT END 2021
    * FDA REGULATORY SUBMISSION PLANNED FOR MID-2023
    * OUTLOOK 2022: PRIMARY ENDPOINT READ-OUT OF POSEIDON, NORTH
AMERICAN PIVOTAL STUDY OF ALFAPUMP EXPECTED IN Q4 2022 AND START
OF MOJAVE DESERT, FIRST U.S. STUDY WITH COMPANY'S PROPRIETARY
DSR INFUSATE 2.0 IN DECOMPENSATED HEART FAILURE PATIENTS
    * FY NET LOSS EUR 23.6 MILLION VERSUS LOSS OF EUR 19.1
MILLION
YEAR AGO
    * EBIT EVOLVED FROM A LOSS OF EUR 17.77 MILLION IN 2020 TO A
LOSS
OF EUR 22.61 MILLION IN 2021
    * POSEIDON: PREMARKET APPROVAL (PMA) SUBMISSION TO U.S. FDA
EXPECTED IN MID-2023
    * SAHARA DESERT – PHASE 2A SAFETY AND FEASIBILITY STUDY OF
ALFAPUMP DSR IN DECOMPENSATED HEART FAILURE PATIENTS: REPORTING
OF TOP-LINE DATA EXPECTED IN H2 2022
    * MOJAVE DESERT: STUDY DUE TO COMMENCE BEFORE END OF YEAR
    * REVENUE DECREASED FROM EUR 0.96 MILLION IN 2020 TO EUR
0.37
MILLION IN 2021

Source text for Eikon:  ID:nGNX8zLSLV 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))